The Greater Baltimore Committee last week offered testimony supporting a bill intended to more aggressively focus use of the state’s stem cell research funding on supporting commercialization of research.
HB 289, sponsored by Delegate Brian Feldman (D-Montgomery), requires that at least one-third of grants be awarded to for-profit companies in the state. It also requires that, in selecting nonprofit grant recipients, priority be given to applicants that have co-development partnerships with Maryland for-profit companies. It was heard on February 7 by the House Health and Government Operations Committee.
A Senate companion bill, SB 399, is sponsored by Senators Catherine Pugh (D-Baltimore City), Jennie Forehand (D-Montgomery) and Rob Garagiola (D-Montgomery). It will be heard on February 23 by the Finance Committee.